Bicarbonate Therapy in End-Stage Renal Disease: Current Practice Trends and Implications

Jagannath H. Saikumar, Csaba Kovesdy

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Management of metabolic acidosis covers the entire spectrum from oral bicarbonate therapy and dietary modifications in chronic kidney disease to delivery of high doses of bicarbonate-based dialysate during maintenance haemodialysis (MHD). Due to the gradual depletion of the body's buffers and rapid repletion during MHD, many potential problems arise as a result of our current treatment paradigms. Several studies have given rise to conflicting data about the adverse effects of our current practice patterns in MHD. In this review, we will describe the pathophysiology and consequences of metabolic acidosis and its therapy in CKD and ESRD, and discuss current evidence supporting a more individualized approach for bicarbonate therapy in MHD.

Original languageEnglish (US)
Pages (from-to)370-376
Number of pages7
JournalSeminars in Dialysis
Volume28
Issue number4
DOIs
StatePublished - Jul 1 2015

Fingerprint

Bicarbonates
Chronic Kidney Failure
Renal Dialysis
Maintenance
Acidosis
Diet Therapy
Dialysis Solutions
Therapeutics
Chronic Renal Insufficiency
Buffers

All Science Journal Classification (ASJC) codes

  • Nephrology

Cite this

Bicarbonate Therapy in End-Stage Renal Disease : Current Practice Trends and Implications. / Saikumar, Jagannath H.; Kovesdy, Csaba.

In: Seminars in Dialysis, Vol. 28, No. 4, 01.07.2015, p. 370-376.

Research output: Contribution to journalArticle

@article{ac323175922248f5a314dcd0eb05d8e9,
title = "Bicarbonate Therapy in End-Stage Renal Disease: Current Practice Trends and Implications",
abstract = "Management of metabolic acidosis covers the entire spectrum from oral bicarbonate therapy and dietary modifications in chronic kidney disease to delivery of high doses of bicarbonate-based dialysate during maintenance haemodialysis (MHD). Due to the gradual depletion of the body's buffers and rapid repletion during MHD, many potential problems arise as a result of our current treatment paradigms. Several studies have given rise to conflicting data about the adverse effects of our current practice patterns in MHD. In this review, we will describe the pathophysiology and consequences of metabolic acidosis and its therapy in CKD and ESRD, and discuss current evidence supporting a more individualized approach for bicarbonate therapy in MHD.",
author = "Saikumar, {Jagannath H.} and Csaba Kovesdy",
year = "2015",
month = "7",
day = "1",
doi = "10.1111/sdi.12373",
language = "English (US)",
volume = "28",
pages = "370--376",
journal = "Seminars in Dialysis",
issn = "0894-0959",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Bicarbonate Therapy in End-Stage Renal Disease

T2 - Current Practice Trends and Implications

AU - Saikumar, Jagannath H.

AU - Kovesdy, Csaba

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Management of metabolic acidosis covers the entire spectrum from oral bicarbonate therapy and dietary modifications in chronic kidney disease to delivery of high doses of bicarbonate-based dialysate during maintenance haemodialysis (MHD). Due to the gradual depletion of the body's buffers and rapid repletion during MHD, many potential problems arise as a result of our current treatment paradigms. Several studies have given rise to conflicting data about the adverse effects of our current practice patterns in MHD. In this review, we will describe the pathophysiology and consequences of metabolic acidosis and its therapy in CKD and ESRD, and discuss current evidence supporting a more individualized approach for bicarbonate therapy in MHD.

AB - Management of metabolic acidosis covers the entire spectrum from oral bicarbonate therapy and dietary modifications in chronic kidney disease to delivery of high doses of bicarbonate-based dialysate during maintenance haemodialysis (MHD). Due to the gradual depletion of the body's buffers and rapid repletion during MHD, many potential problems arise as a result of our current treatment paradigms. Several studies have given rise to conflicting data about the adverse effects of our current practice patterns in MHD. In this review, we will describe the pathophysiology and consequences of metabolic acidosis and its therapy in CKD and ESRD, and discuss current evidence supporting a more individualized approach for bicarbonate therapy in MHD.

UR - http://www.scopus.com/inward/record.url?scp=84935716364&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84935716364&partnerID=8YFLogxK

U2 - 10.1111/sdi.12373

DO - 10.1111/sdi.12373

M3 - Article

C2 - 25845518

AN - SCOPUS:84935716364

VL - 28

SP - 370

EP - 376

JO - Seminars in Dialysis

JF - Seminars in Dialysis

SN - 0894-0959

IS - 4

ER -